Diseases / Pulmonary Embolism
Pulmonary Embolism
DiseasePulmonary embolism is an acute obstruction of pulmonary arteries, usually by thrombus, that can cause dyspnea, chest pain, right heart strain, and sudden death if severe.
- Trials
- 775
- Recruiting
- 99
- Completed
- 427
- With results
- 98
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | 1 | — | — | 6 | 1 | — | — | 1 | 11 |
| Phase 1 | — | — | — | — | 8 | 1 | — | — | 2 | 11 |
| Phase 1/2 | — | — | — | — | 2 | 1 | — | — | 1 | 4 |
| Phase 2 | — | — | — | 1 | 15 | 3 | 2 | — | 1 | 22 |
| Phase 2/3 | — | — | — | — | 6 | 1 | — | — | 2 | 9 |
| Phase 3 | 12 | — | — | 2 | 42 | 10 | 4 | — | 2 | 72 |
| Phase 4 | 5 | 1 | — | 4 | 38 | 7 | 6 | — | 7 | 68 |
| Not applicable | 39 | 7 | — | 8 | 120 | 12 | 5 | 2 | 29 | 222 |
| Unknown | 41 | 12 | 2 | 8 | 190 | 11 | 11 | 2 | 79 | 356 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulmonary Embolism | 11 | 11 | 4 | 22 | 9 | 72 | 68 | 222 | 356 | 775 |
| Venous Thrombosis | 6 | 6 | 1 | 10 | 6 | 42 | 30 | 69 | 120 | 290 |
| Venous Thromboembolism | 7 | 6 | 2 | 8 | 3 | 32 | 16 | 32 | 73 | 179 |
| Thrombosis | 1 | 1 | — | 5 | — | 7 | 6 | 14 | 33 | 67 |
| Atrial Fibrillation | — | — | — | 1 | 1 | 2 | 7 | 15 | 21 | 47 |
| Thromboembolism | 1 | — | — | 1 | 2 | 5 | 4 | 3 | 16 | 32 |
| Neoplasms | — | — | — | 2 | — | 5 | 1 | 7 | 14 | 29 |
| Disease | — | — | — | — | — | 1 | — | 9 | 17 | 27 |
| COVID-19 | — | — | — | 1 | — | 2 | — | 4 | 19 | 26 |
| Hypertension, Pulmonary | 1 | 1 | — | — | — | 1 | 1 | 5 | 11 | 20 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Brigham and Women's Hospital | 26 | 0 |
| 2 | University Hospital, Brest | 19 | 1 |
| 3 | Assistance Publique - Hôpitaux de Paris | 17 | 3 |
| 4 | Bayer | 15 | 4 |
| 5 | Assiut University | 13 | 0 |
| 6 | Centre Hospitalier Universitaire de Saint Etienne | 10 | 2 |
| 7 | McMaster University | 10 | 4 |
| 8 | University Hospital, Angers | 10 | 1 |
| 9 | Ottawa Hospital Research Institute | 9 | 0 |
| 10 | University of Utah | 9 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Enoxaparin | 43 |
| 2 | Rivaroxaban | 36 |
| 3 | apixaban | 26 |
| 4 | Warfarin | 24 |
| 5 | Heparin, Low-Molecular-Weight | 23 |
| 6 | Dalteparin | 20 |
| 7 | Heparin | 20 |
| 8 | Tissue Plasminogen Activator | 17 |
| 9 | Fondaparinux | 14 |
| 10 | Tinzaparin | 11 |
Evidence
- Results reported
- 23%98 of 427 completed
- Published
- 14.8%63 of 427 completed
- Primary endpoint met
- 59.6%31 of 52 analyses
- Median months to report
- 14.5
Documents disclosed
Trial profile
- Median enrollment
- 253
- Median duration
- 31months
- Countries
- 95
- Study sites
- 5714
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 60
- Phase 1
- 24
- Phase 1/2
- 118
- Phase 2
- 79
- Phase 2/3
- 306
- Phase 3
- 493
- Phase 4
- 145
- Not applicable
- 160
- Unknown
- 355
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 61 |
| 2 | Paris | France | 60 |
| 3 | Brest | France | 49 |
| 4 | New York | United States | 42 |
| 5 | Beijing | China | 38 |
| 6 | Ottawa | Canada | 36 |
| 7 | Philadelphia | United States | 36 |
| 8 | Saint-Etienne | France | 35 |
| 9 | Clermont-Ferrand | France | 34 |
| 10 | Angers | France | 33 |
Terminations
- Terminated
- 47
- Withdrawn
- 28
- Suspended
- 4
- Stopped for recruitment
- 2.1%16 of 775 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06189313 Suspended | Suspended | Enrollment in the study administratively paused pending modifications to the study device design | 2029-02-02 |
| NCT06310018 Suspended | Suspended | Awaiting completion and reporting of related trial | 2028-12-31 |
| NCT04996667 Withdrawn | Withdrawn | no sponsor support | 2028-06-30 |
| NCT05946811 Withdrawn | Withdrawn | Study was cancelled by funding agency before starting enrollment. | 2028-06-01 |
| NCT05171075 Terminated | Terminated | Sponsor Decision | 2026-04-10 |
| NCT05171049 Terminated | Terminated | Sponsor decision | 2026-02-04 |
| NCT04855370 Withdrawn | Withdrawn | Study device no longer available | 2025-12-31 |
| NCT04059965 Withdrawn | Withdrawn | Lack of funding | 2025-09-30 |
| NCT06415968 Terminated | Terminated | difficulty of inclusion, PI decision | 2025-02-11 |
| NCT02983760 Terminated | Terminated | The enrollment process for patients is difficult. | 2024-12-17 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Pulmonary Embolism trials on ClinicalTrials.gov →